Collectively, in vivo experiments showed that the FAK inhibitor defactinib (VS6063) can suppress NSCLC metastasis induced by overexpression of FTO, indicating a novel treatment strategy for NSCLC metastasis. This evidence concerns the gene FTO and non-small cell lung carcinoma.